Predicting stroke risk in hypertensive patients with coronary artery disease: A report from the INVEST

Stroke

Volumn 39, Issue 2, 2008, Pages 343-348

  Coca, Antonio ^a   Messerli, Franz H ^b   Benetos, Athanase ^c   Zhou, Qian ^d   Champion, Annette ^d   Cooper DeHoff, Rhonda M ^e   Pepine, Carl J ^e  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Medical School of Nancy   (France)

^d ABBOTT LABORATORIES   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atenolol; Coronary artery disease; Hydrochlorothiazide; Hypertension; Stroke; Trandolapril; Verapamil SR

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL; ANTIHYPERTENSIVE AGENT; INDOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; SMOKING; STROKE; TRANSIENT ISCHEMIC ATTACK; FACTUAL DATABASE; MIDDLE AGED; NEGRO; PREDICTION AND FORECASTING; RISK FACTOR; STATISTICS; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; UNITED STATES; VERAPAMIL;

EID: 39349104702     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.495465     Document Type: Article

References (30)

1. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke: the Framingham study. JAMA. 1983;250:2942-2946.
2. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
5. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
6. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
7. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
8. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, Zellig P. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32:1228-1237.
9. Elliott WJ, Hewkin AC, Kupfer S, Cooper-DeHoff R, Pepine CJ. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. J Clin Hypertens (Greenwich). 2005;7:654-663.
10. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 2001;103:163-182.
11. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143:785-792.
12. Chimowitz MI, Poole RM, Starling MR, Schwaiger M, Gross MD. Frequency and severity of asymptomatic coronary disease in patients with different causes of stroke. Stroke. 1997;28:941-945.
13. Rokey R, Rolak LA, Harati Y, Kutka N, Verani MS. Coronary artery disease in patients with cerebrovascular disease: a prospective study. Ann Neurol. 1984;16:50-53.
14. Dexter DD Jr, Whisnant JP, Connolly DC, O'Fallon WM. The association of stroke and coronary heart disease: a population study. Mayo Clin Proc. 1987;62:1077-1083.
15. Cronin L, Mehta SR, Zhao F, Pogue J, Budaj A, Hunt D, Yusuf S. Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving >18 000 patients. Circulation. 2001;104:269-274.
16. Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, Behar S. Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction: the SPRINT Study Group. Stroke. 1993;24:1490-1495.
17. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
18. Mooe T, Olofsson BO, Stegmayr B, Eriksson P. Ischemic stroke: impact of a recent myocardial infarction. Stroke. 1999;30:997-1001.
19. Lichtman JH, Krumholz HM, Wang Y, Radford MJ, Brass LM. Risk and predictors of stroke after myocardial infarction among the elderly: results from the Cooperative Cardiovascular Project. Circulation. 2002;105:1082-1087.
20. Fuchs S, Stabile E, Kinnaird TD, Mintz GS, Gruberg L, Canos DA, Pinnow EE, Kornowski R, Suddath WO, Satler LF, Pichard AD, Kent KM, Weissman NJ. Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation. 2002;106:86-91.
21. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? the Framingham Heart Study. Circulation. 2001;103:1245-1249.
22. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
23. Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Curr Cardiol Rep. 2004;6:124-129.
24. van Wijk I, Kappelle LJ, van Gijn J, Koudstaal PJ, Franke CL, Vermeulen M, Gorter JW, Algra A. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365:2098-2104.
25. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ. 1997;315:154-159.
26. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
27. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
28. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-2446.
29. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? a meta-analysis. Lancet. 2005;366:1545-1553.
30. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534 -2544.